{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":186,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":186,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"65026dd2c025","filters":{"venue":"Clinical Lung Cancer"}},"results":[{"id":"W1969531640","doi":"10.1016/j.cllc.2014.04.003","title":"An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Recursive partitioning; Radiosurgery; Internal medicine; Oncology; Radiation therapy; Proportional hazards model; Lung cancer; Adenocarcinoma; Multivariate analysis; Primary tumor; Cancer; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.120434245352355,"gpt":0.4722635767882877,"spread":0.3518293314359326,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000396697,0.000911955,0.006811211,0.0003205376,0.00004696219,0.00003482592,0.0004133635,0.0004053127,0.0003596166],"category_scores_gemma":[0.0001503215,0.0005358303,0.001285921,0.0004136227,0.0002580812,0.0001007642,0.0002486517,0.0003031268,0.000002311123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005219288,"about_ca_system_score_gemma":0.001252941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001218505,"about_ca_topic_score_gemma":0.0007550122,"domain_scores_codex":[0.9943393,0.0004273119,0.002709439,0.001420321,0.0006271718,0.0004764167],"domain_scores_gemma":[0.9936212,0.001739002,0.001803278,0.002095821,0.0002142544,0.0005264825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00005656088,0.002045175,0.5994293,0.02320224,0.01448011,0.00002494466,0.0002188992,0.000003261939,4.645248e-8,9.932214e-7,0.0002743848,0.3602641],"study_design_scores_gemma":[0.007745948,0.006156313,0.2523292,0.03975706,0.5510722,0.000008477293,0.000110299,0.0006342615,0.00002390143,0.000003924254,0.1406396,0.001518669],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06634706,0.9249544,0.00001275562,0.00006606898,0.0005168798,0.003524399,0.004527113,0.00002124364,0.00003004887],"genre_scores_gemma":[0.05084671,0.9446784,0.000486114,0.00008762764,0.0002140483,0.002070315,0.001396612,0.0001128866,0.0001072594],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5365921,"threshold_uncertainty_score":0.9997093,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2030485399","doi":"10.3816/clc.2006.n.030","title":"K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung; Oncology; Internal medicine; Carcinoma; Small Cell Lung Carcinoma; Cancer research; Mutation; Small-cell carcinoma; Genetics; Gene; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0674510554685044,"gpt":0.4797817026109228,"spread":0.4123306471424185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049148,0.0006378087,0.00358856,0.0002359228,0.00008948099,0.00002828257,0.0002598782,0.0005522314,0.0004722901],"category_scores_gemma":[0.0001578648,0.0004848968,0.001418248,0.0008749522,0.0001227653,0.00006467564,0.00008554955,0.001119866,0.0001214422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001278097,"about_ca_system_score_gemma":0.003565866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007662735,"about_ca_topic_score_gemma":0.0004614501,"domain_scores_codex":[0.9955606,0.0002445239,0.002354219,0.000989648,0.0003081359,0.0005428451],"domain_scores_gemma":[0.997268,0.0006374113,0.0007345568,0.0008415385,0.0001931571,0.0003253232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001219875,0.0008024215,0.01451543,0.1817009,0.000624546,0.0003326783,0.00003475775,0.000003119639,2.739521e-8,0.000016479,0.1198142,0.6821432],"study_design_scores_gemma":[0.001862608,0.00009350861,0.002430471,0.1150726,0.02130019,0.00002484936,0.000005638618,0.0000454108,7.81581e-8,0.000006031407,0.8587356,0.0004230519],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004722118,0.9809916,0.0000302404,0.0004576244,0.00102159,0.00582698,0.0002742499,0.00006338546,0.01128712],"genre_scores_gemma":[0.00005816299,0.9833274,0.0003522985,0.001252752,0.0009829235,0.003453611,0.001224806,0.0001368716,0.009211196],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7389213,"threshold_uncertainty_score":0.9997603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086142513","doi":"10.3816/clc.2001.n.018","title":"Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer","year":2001,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":162,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Immunotherapy; Vaccination; Immunogenicity; Lung cancer; Cancer vaccine; Immunology; Immune system; Peptide vaccine; Internal medicine; MUC1; Cancer; Oncology; Gastroenterology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.03284774457342199,"gpt":0.3810141725328872,"spread":0.3481664279594652,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008893522,0.0004329848,0.001040134,0.0001511824,0.0002999332,0.00002294258,0.000841558,0.0004518249,0.001959963],"category_scores_gemma":[0.00009063089,0.0003183754,0.0004857585,0.0004485598,0.0002339494,0.0001427304,0.0001468219,0.0009190094,0.00001093737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002365385,"about_ca_system_score_gemma":0.0004550226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001051811,"about_ca_topic_score_gemma":0.0009464,"domain_scores_codex":[0.9962337,0.000801963,0.001477327,0.0006894694,0.00009145979,0.0007060923],"domain_scores_gemma":[0.9969426,0.001199158,0.0006871945,0.0009298624,0.0002063569,0.00003487053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.08802296,0.01866898,0.3364715,0.0001860772,0.003445411,0.00002253021,0.008149855,0.0002382184,0.4466326,0.00004307395,0.01237942,0.08573935],"study_design_scores_gemma":[0.1553159,0.007955039,0.4834191,0.0007862917,0.0006404183,0.0000161251,0.004482305,0.0003099196,0.109884,0.00002635931,0.2357641,0.00140044],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9527614,0.04014684,0.00008709752,0.0004245512,0.002850218,0.003307719,0.000156122,0.00003777722,0.0002283052],"genre_scores_gemma":[0.9669158,0.01344023,0.00002318377,0.0005041074,0.0002305863,0.0008638757,0.00002038976,0.00008004037,0.01792178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3367486,"threshold_uncertainty_score":0.9999268,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101035251","doi":"10.3816/clc.2006.n.022","title":"Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2006,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Epidermal growth factor receptor; Clinical trial; Oncology; Internal medicine; Cancer; Erlotinib Hydrochloride","retraction":null,"screen_n_in":null,"score":{"opus":0.05956746420320729,"gpt":0.4022416275421409,"spread":0.3426741633389336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001520285,0.0003129774,0.00130491,0.00008684403,0.0001038506,0.00001187189,0.0002064231,0.0002076013,0.0002630689],"category_scores_gemma":[0.0007881542,0.0002021233,0.0002224659,0.0001689662,0.0002146903,0.0001497864,0.0000554597,0.0003770262,9.396616e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001187712,"about_ca_system_score_gemma":0.003596367,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.305432,"about_ca_topic_score_gemma":0.330388,"domain_scores_codex":[0.9956407,0.0004117015,0.00212045,0.0006629173,0.0008319211,0.0003322935],"domain_scores_gemma":[0.9948868,0.002861933,0.001180108,0.0002512043,0.0006370614,0.0001828715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002114887,0.001703741,0.9826997,0.0001991479,0.0007707365,0.000003145791,0.0005617815,0.0001534733,0.00005329977,0.00002048473,0.01057554,0.001144092],"study_design_scores_gemma":[0.01752285,0.0007245467,0.9758659,0.0006931812,0.001518568,1.403448e-7,0.0001472847,0.0002061926,0.00007765795,0.0000167874,0.003010705,0.0002161592],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986828,0.002776419,0.00003798172,0.0003892063,0.003591608,0.003714697,0.0024009,0.00001328471,0.0002479072],"genre_scores_gemma":[0.9958788,0.0003996685,0.0002159465,0.000414512,0.001336902,0.001094907,0.000236275,0.00004402552,0.0003790365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02495601,"threshold_uncertainty_score":0.8242347,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2802496191","doi":"10.1016/j.cllc.2018.04.008","title":"Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Lung Cancer Canada","keywords":"Medicine; Internal medicine; Lung cancer; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Lymphocyte; Cancer; Oncology; Gastroenterology; Immunology; Chemotherapy; Neutropenia","retraction":null,"screen_n_in":null,"score":{"opus":0.008905247391622071,"gpt":0.3035545086133777,"spread":0.2946492612217557,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002639655,0.0003882222,0.0008064623,0.0001716583,0.00009754044,0.00002396203,0.0001409348,0.0001882445,0.00006982317],"category_scores_gemma":[0.00006075771,0.000265026,0.0000817258,0.0004855152,0.0004700491,0.0001948934,0.00008547529,0.0002675318,0.000003557609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005466831,"about_ca_system_score_gemma":0.0008907194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002547065,"about_ca_topic_score_gemma":0.001001782,"domain_scores_codex":[0.997321,0.0000786257,0.0008803457,0.0007394686,0.0005380722,0.0004425217],"domain_scores_gemma":[0.9977496,0.000160163,0.0004880721,0.0005088893,0.0007159436,0.0003773462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01540426,0.0003411935,0.9792917,0.0003893911,0.0003145398,0.00002427786,0.0003020751,0.0006267132,0.0000567534,0.000004592287,0.0005353175,0.002709131],"study_design_scores_gemma":[0.01544509,0.002102305,0.976375,0.001632713,0.0006847275,0.000001419843,0.00004234914,0.002791818,0.0003225221,0.000001323345,0.0002316218,0.0003691138],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953576,0.0007135556,0.0001528282,0.0004619893,0.0004753573,0.002499246,0.00006398765,0.00004472607,0.0002307612],"genre_scores_gemma":[0.9963409,0.0001948485,0.001338267,0.001127139,0.0002540275,0.0004787836,0.00002292476,0.00008145885,0.0001616214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002916761,"threshold_uncertainty_score":0.9999802,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1980672928","doi":"10.1016/j.cllc.2012.01.003","title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Erlotinib Hydrochloride; Placebo; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Phases of clinical research; Epidermal growth factor receptor; Population; Clinical trial; Pharmacology; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06581369968642774,"gpt":0.4234511069001325,"spread":0.3576374072137048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001137206,0.0005093708,0.002261824,0.0002314117,0.00009884137,0.00002085676,0.0001681395,0.0001646978,0.0003738902],"category_scores_gemma":[0.0002813017,0.0003407226,0.0001887018,0.0005707858,0.0003231502,0.0002782445,0.00007420247,0.0003760347,0.000001568949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004729109,"about_ca_system_score_gemma":0.002174786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00123686,"about_ca_topic_score_gemma":0.001683124,"domain_scores_codex":[0.9957013,0.0004695381,0.001959335,0.0006916145,0.0005791004,0.0005991852],"domain_scores_gemma":[0.9950494,0.002354188,0.001097791,0.0004714809,0.0006141747,0.0004129842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8745722,0.007682243,0.1029064,0.0005627602,0.002682317,0.00002325761,0.004685641,0.00386427,0.0000249321,0.000009721338,0.0003676422,0.00261864],"study_design_scores_gemma":[0.9717525,0.004508546,0.006709479,0.0009271642,0.008166714,0.000002389211,0.0009304098,0.006331748,0.0002162838,0.000001033208,0.00006574797,0.0003879703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9532639,0.003771293,0.001555062,0.00008819528,0.000484265,0.04032757,0.0001739848,0.00003841853,0.0002973086],"genre_scores_gemma":[0.9859086,0.0009790069,0.003020543,0.0001091237,0.0001392651,0.008151788,0.0001566995,0.00009167226,0.001443357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09718031,"threshold_uncertainty_score":0.9999045,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2460186095","doi":"10.1016/j.cllc.2016.07.002","title":"Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small-Cell Lung Cancer: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Windsor Regional Hospital; McMaster University; Cancer Care Ontario; Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Bevacizumab; Adjuvant therapy; Systematic review; Cochrane Library; Randomized controlled trial; Chemotherapy; Adjuvant; Clinical trial; Meta-analysis; MEDLINE","retraction":null,"screen_n_in":null,"score":{"opus":0.09170367555303513,"gpt":0.462173895574565,"spread":0.3704702200215299,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001703431,0.001320169,0.01292475,0.0002779834,0.0001134078,0.00005736758,0.0006925857,0.0008140188,0.0007604528],"category_scores_gemma":[0.0004315649,0.0007308957,0.002150975,0.0008384305,0.0001698588,0.00008734057,0.0001761899,0.001354647,0.0001502081],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004739465,"about_ca_system_score_gemma":0.004296586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005594283,"about_ca_topic_score_gemma":0.000370088,"domain_scores_codex":[0.989943,0.001757402,0.004867793,0.001782169,0.0007167695,0.0009329114],"domain_scores_gemma":[0.9926024,0.002293961,0.002128308,0.001822569,0.0005929762,0.0005598015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001080146,0.0005141936,0.002166101,0.8945628,0.002823582,0.0002804754,0.00006924329,4.412726e-7,5.465366e-7,0.000008244215,0.0177575,0.08170882],"study_design_scores_gemma":[0.004109839,0.000612908,0.0001290034,0.8983176,0.0136036,0.0000766489,0.00000804771,0.00003667657,0.000001236166,8.728096e-7,0.08237072,0.0007328818],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001322417,0.9699631,0.000006251826,0.001070233,0.001620293,0.02603143,0.0006200672,0.0001044607,0.0004518996],"genre_scores_gemma":[0.0002167218,0.9684576,0.00002867734,0.002833426,0.0008400732,0.02515507,0.0001739599,0.0002420071,0.002052432],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.08097593,"threshold_uncertainty_score":0.9999549,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2800790347","doi":"10.1016/j.cllc.2018.04.001","title":"SUNSET: Stereotactic Radiation for Ultracentral Non–Small-Cell Lung Cancer—A Safety and Efficacy Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Hôpital Notre-Dame; Cancer Care Ontario; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Esophagus; Radiology; Mediastinum; Esophageal cancer; Radiation therapy; Stage (stratigraphy); Surgery; Oncology; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03527258019562635,"gpt":0.4095300295095076,"spread":0.3742574493138812,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004719651,0.0002857479,0.0007230928,0.00005260412,0.0001891597,0.00005048593,0.0001042344,0.0002428462,0.0004325983],"category_scores_gemma":[0.0002109801,0.0002290663,0.0003026708,0.0001437441,0.0001757466,0.0000934569,0.00003366786,0.0002583304,0.00000939146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000692989,"about_ca_system_score_gemma":0.0006641813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003367142,"about_ca_topic_score_gemma":0.0003942065,"domain_scores_codex":[0.9976435,0.00008391594,0.0008268203,0.0007123703,0.000223906,0.0005094588],"domain_scores_gemma":[0.9977003,0.0009859592,0.0003143645,0.0003917846,0.000195846,0.0004117886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09291908,0.002062534,0.7354602,0.0009471218,0.001642302,0.00001921372,0.0006515037,0.00001910177,0.00007918249,0.00006872301,0.06001825,0.1061128],"study_design_scores_gemma":[0.3212628,0.006298398,0.555155,0.001297348,0.006759923,0.000007410323,0.00004420124,0.008190831,0.001796152,0.00001864205,0.09842759,0.0007417577],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752545,0.008945896,0.0002645562,0.004948235,0.004529506,0.005113123,0.0002061451,0.00007230901,0.0006657013],"genre_scores_gemma":[0.9732465,0.01386387,0.0002968564,0.002100382,0.007837103,0.0008634586,0.00007501098,0.00006832461,0.001648549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2283437,"threshold_uncertainty_score":0.9341052,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061817827","doi":"10.1016/j.cllc.2014.07.005","title":"Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Concomitant; Oncology; Erlotinib Hydrochloride; Population; Adenocarcinoma; Retrospective cohort study; Cancer; Epidermal growth factor receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.03680941315444405,"gpt":0.3661857580732465,"spread":0.3293763449188024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001013698,0.0003490556,0.001103776,0.00012001,0.000114812,0.00002501561,0.0001692663,0.0002356359,0.0009161179],"category_scores_gemma":[0.0007256534,0.0002449855,0.0002779459,0.00051736,0.0001477258,0.00005375838,0.0001046979,0.0006664441,0.00001280599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002293279,"about_ca_system_score_gemma":0.0003904713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004079942,"about_ca_topic_score_gemma":0.0006990157,"domain_scores_codex":[0.9970368,0.0002951524,0.0008691319,0.0007374689,0.0004532876,0.0006082184],"domain_scores_gemma":[0.997754,0.0007139186,0.0003540522,0.000504412,0.0002574167,0.000416161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009819812,0.0008700019,0.9351673,0.0002295171,0.000332167,0.0000757685,0.0002051413,0.00002789765,0.0005466178,0.000003433998,0.04802347,0.01353673],"study_design_scores_gemma":[0.01337146,0.0005558018,0.9723564,0.001814376,0.001318923,0.000005528881,0.00006092967,0.005228466,0.00155322,0.000002492564,0.003367611,0.0003648321],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988426,0.006171889,0.00009512206,0.001416537,0.0005406632,0.001043536,0.00006480565,0.00005981875,0.002181684],"genre_scores_gemma":[0.9933684,0.001511987,0.0002338583,0.002681373,0.0005916681,0.0002685007,0.00004058295,0.00006154086,0.001242089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04465586,"threshold_uncertainty_score":0.9999972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2589103622","doi":"10.1016/j.cllc.2017.02.001","title":"Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review","year":2017,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Pemetrexed; Nivolumab; Internal medicine; Oncology; Erlotinib; Lung cancer; Hazard ratio; Docetaxel; Adverse effect; Gefitinib; Chemotherapy; Erlotinib Hydrochloride; Epidermal growth factor receptor; Cancer; Immunotherapy; Confidence interval; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.0542220111495793,"gpt":0.4328983314420488,"spread":0.3786763202924694,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001761478,0.001113158,0.009390503,0.0001417918,0.000264143,0.00007533989,0.0007982936,0.0007309461,0.0001973294],"category_scores_gemma":[0.0006757211,0.0006966112,0.003422855,0.0003330067,0.000266935,0.000126587,0.0001500179,0.001038734,0.00001395393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001239896,"about_ca_system_score_gemma":0.0030112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001219203,"about_ca_topic_score_gemma":0.00005892661,"domain_scores_codex":[0.9925739,0.0002744697,0.004481616,0.001298878,0.0005885652,0.000782642],"domain_scores_gemma":[0.9912592,0.0007154936,0.004835337,0.002171535,0.0006386427,0.0003797783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0005962002,0.0002940893,0.0004280815,0.760839,0.002422559,0.000008093878,0.00001528071,1.14827e-7,3.197532e-7,3.962924e-7,0.004180857,0.231215],"study_design_scores_gemma":[0.004306166,0.0005397195,0.00007367997,0.620988,0.02306928,0.000004523376,0.000002956652,0.00001135341,0.000001553245,2.989404e-7,0.3504078,0.0005946839],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005713684,0.9681483,0.00002447058,0.0002414596,0.002819763,0.02793255,0.0004448774,0.00007926948,0.0002522095],"genre_scores_gemma":[0.00001476992,0.9779879,0.0002374036,0.0008437759,0.0009459504,0.01563559,0.0003687108,0.0002693559,0.003696554],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3462269,"threshold_uncertainty_score":0.9995485,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2532789950","doi":"10.1016/j.cllc.2016.10.007","title":"ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Internal medicine; Hazard ratio; Lung cancer; Cohort; Retrospective cohort study; Incidence (geometry); Oncology; Cancer; ROS1; Adenocarcinoma; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02597795368836974,"gpt":0.3429445641154291,"spread":0.3169666104270594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008057203,0.0003864869,0.001850288,0.0001045616,0.0001085891,0.0000213108,0.0002873627,0.0003182881,0.002017168],"category_scores_gemma":[0.0001947474,0.0002433705,0.0003353927,0.0003466423,0.0002929441,0.00009842693,0.0001339532,0.0003535975,0.00002922116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003575433,"about_ca_system_score_gemma":0.000631305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001880912,"about_ca_topic_score_gemma":0.0007269067,"domain_scores_codex":[0.9970089,0.0001681303,0.0009607798,0.0007677396,0.0004088,0.0006856071],"domain_scores_gemma":[0.9973498,0.0005333392,0.0006093208,0.0007202332,0.0004339348,0.0003534025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001607647,0.009061376,0.5332446,0.001823241,0.01011589,0.0002802104,0.002021546,0.00007107101,0.01028264,0.0004223935,0.3896441,0.04142525],"study_design_scores_gemma":[0.01384159,0.001554215,0.9572685,0.005040275,0.005601818,0.000002179946,0.00006430896,0.0003047544,0.005756201,0.000103145,0.009789161,0.0006738927],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832453,0.002932683,0.0001450986,0.006695852,0.001152851,0.00166187,0.0001935768,0.0001073722,0.003865413],"genre_scores_gemma":[0.9804498,0.008089689,0.0001402489,0.005898178,0.0007000144,0.0004515119,0.00001747152,0.0001078245,0.004145254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4240238,"threshold_uncertainty_score":0.9988951,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2567886556","doi":"10.1016/j.cllc.2016.12.010","title":"Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Trillium Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Intensive care medicine; Cancer; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02672409037937641,"gpt":0.4285317237315859,"spread":0.4018076333522095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003825863,0.0001877601,0.0007743596,0.00006410004,0.0001101847,0.00001241047,0.000328902,0.000263831,0.0007807857],"category_scores_gemma":[0.0004385968,0.00016428,0.000385861,0.0001179841,0.0003764039,0.000148794,0.0001344994,0.0003605051,0.000002335141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003841082,"about_ca_system_score_gemma":0.0007371808,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009996198,"about_ca_topic_score_gemma":0.003915565,"domain_scores_codex":[0.9979849,0.00005986415,0.0007978851,0.000430531,0.0004265509,0.0003002553],"domain_scores_gemma":[0.9975532,0.0001983072,0.0007017553,0.0009605324,0.0003771439,0.0002090031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001186166,0.0001017649,0.9597262,0.0008118362,0.0003536289,0.000006612502,0.0004663806,0.0001573874,0.0024645,0.0003298349,0.005194359,0.0292014],"study_design_scores_gemma":[0.004276067,0.0002411965,0.9721117,0.002558812,0.0009154248,0.000001845454,0.0001720257,0.003476959,0.001921646,0.00009022145,0.013963,0.0002711308],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725735,0.01947924,0.000121067,0.001156863,0.002673843,0.0005378491,0.0001401511,0.00003407547,0.003283444],"genre_scores_gemma":[0.9930521,0.003062213,0.00007292784,0.0002092418,0.001335101,0.0001187343,0.000006782003,0.00003518339,0.002107669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02893027,"threshold_uncertainty_score":0.9965963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2189143821","doi":"10.1016/j.cllc.2015.09.007","title":"Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Meta-analysis; Oncology; Radiology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.4089820723585534,"gpt":0.6118290681439336,"spread":0.2028469957853802,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.003928778,0.001373339,0.01681764,0.0006601655,0.0002249075,0.0001127855,0.0009109352,0.001007424,0.002215087],"category_scores_gemma":[0.001004806,0.0008971493,0.01379709,0.001969804,0.0005109768,0.0001041426,0.0003346941,0.00198743,0.00001972608],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003007435,"about_ca_system_score_gemma":0.007213742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006285594,"about_ca_topic_score_gemma":0.0006336087,"domain_scores_codex":[0.9909355,0.001097238,0.002950151,0.002358385,0.001280793,0.001377927],"domain_scores_gemma":[0.9896223,0.003261271,0.001741611,0.00214643,0.002132885,0.001095485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004968272,0.0002726034,0.0006165982,0.05531236,0.5352566,0.00009063247,0.0001095377,0.00003472038,2.073603e-7,0.00001184204,0.1282303,0.2795677],"study_design_scores_gemma":[0.0009835765,0.0002265556,0.00001037736,0.001271644,0.4431104,0.000002366568,0.00001467126,0.0003903155,5.944228e-7,0.000003555798,0.5534877,0.0004982825],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006613453,0.9819186,0.0007987004,0.001476558,0.001175861,0.01055252,0.003345804,0.0001625974,0.0005627226],"genre_scores_gemma":[0.000002066535,0.929442,0.001697604,0.001596824,0.003013561,0.01487654,0.0003139734,0.0003156906,0.04874178],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4252573,"threshold_uncertainty_score":0.9999017,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2465405903","doi":"10.1016/j.cllc.2016.06.006","title":"Immunotherapy Comes of Age in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunosurveillance; Immunotherapy; Lung cancer; Immunology; Immune system; Immune checkpoint; Cancer; Vaccine therapy; Cytotoxic T cell; Oncology; Cancer research; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0805236080097743,"gpt":0.4954513678020203,"spread":0.4149277597922459,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001036987,0.0005820283,0.004277185,0.000275391,0.0000367282,0.00001599626,0.0004486461,0.0008624683,0.003396501],"category_scores_gemma":[0.00009960957,0.0003702657,0.001872485,0.0005591387,0.0004849408,0.0000640189,0.00007926357,0.0008572994,0.00001196817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009224263,"about_ca_system_score_gemma":0.002061601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004714418,"about_ca_topic_score_gemma":0.0003600166,"domain_scores_codex":[0.9953775,0.0003335526,0.002625263,0.0007431286,0.0003981895,0.0005223691],"domain_scores_gemma":[0.9968494,0.0009137174,0.001061902,0.0009025239,0.0001138394,0.0001586328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009813677,0.000194716,0.008274551,0.01729632,0.002110114,0.00005114683,0.00004261025,9.597017e-8,0.000009618399,0.00001605177,0.01411338,0.95691],"study_design_scores_gemma":[0.003835857,0.0001478572,0.002827123,0.09228892,0.0009943012,0.000007253351,0.000003859883,0.000003978669,0.00000357998,0.000006807197,0.8994722,0.0004082085],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001850144,0.9933308,0.000007814479,0.0004437461,0.002564411,0.002040043,0.0002720783,0.00004599279,0.001110087],"genre_scores_gemma":[0.00005915533,0.9913741,0.00004610166,0.0008272696,0.001114289,0.0007535897,0.00004324235,0.0001351413,0.005647115],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9565018,"threshold_uncertainty_score":0.9998749,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2893221436","doi":"10.1016/j.cllc.2018.09.005","title":"Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Grand River Hospital; University of Victoria","funders":"AstraZeneca Canada","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Adverse effect; Hazard ratio; Cohort; Common Terminology Criteria for Adverse Events; Proportional hazards model; Cancer; Oncology; Renal cell carcinoma; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.0193061778944723,"gpt":0.3678977620764572,"spread":0.3485915841819849,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001868715,0.000231631,0.0008368852,0.0002471607,0.00003674791,0.00000268221,0.00008467123,0.000131799,0.0002229558],"category_scores_gemma":[0.00005071426,0.0001734825,0.0002801059,0.0006221086,0.0002470995,0.0001065308,0.00004268951,0.0001616497,4.624829e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008895418,"about_ca_system_score_gemma":0.0001859963,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001600054,"about_ca_topic_score_gemma":0.002290715,"domain_scores_codex":[0.9981286,0.00006580108,0.0008196901,0.0004874923,0.0002425653,0.000255835],"domain_scores_gemma":[0.9985981,0.0001076512,0.0005180202,0.0003275719,0.0003383656,0.0001102688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03545334,0.001206001,0.9507586,0.0001459757,0.002368043,0.000001950806,0.001204609,0.00004372999,0.0005025252,4.488205e-7,0.00002474026,0.008290068],"study_design_scores_gemma":[0.04254398,0.002822033,0.9465124,0.001024172,0.002734226,1.930348e-7,0.0001481198,0.003169916,0.0008498704,4.173288e-7,0.00003185129,0.0001628082],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997382,0.0008199321,0.0000848502,0.0000639721,0.000267894,0.001199754,0.00007503321,0.00001308959,0.00009347285],"genre_scores_gemma":[0.9979605,0.00120445,0.0002850546,0.00009594536,0.0001165678,0.0001007412,0.00002423488,0.00002691419,0.0001855775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00812726,"threshold_uncertainty_score":0.7074413,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2058344766","doi":"10.1016/j.cllc.2014.08.002","title":"Radical-Intent Hypofractionated Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the Literature","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Western University","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Context (archaeology); Toxicity; Chemoradiotherapy; Pulmonary toxicity; Internal medicine; Oncology; Esophageal cancer; Confidence interval; Acute toxicity; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03086221903032815,"gpt":0.4264149500923849,"spread":0.3955527310620567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00134211,0.0009380504,0.008406254,0.0001137537,0.000126706,0.00004109516,0.0006938669,0.0007991476,0.000227269],"category_scores_gemma":[0.0008646359,0.0004978779,0.004281419,0.0007262361,0.0001982704,0.00007053077,0.00009522869,0.001175845,0.000005449129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002210755,"about_ca_system_score_gemma":0.002884852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004345896,"about_ca_topic_score_gemma":0.00002179359,"domain_scores_codex":[0.9932423,0.0006483,0.003721451,0.001169158,0.0006502813,0.0005684735],"domain_scores_gemma":[0.991675,0.002300881,0.003022957,0.001764774,0.0008464774,0.0003898643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001077107,0.0004504907,0.0001891993,0.8749232,0.003756726,0.000008807639,0.00002097305,0.000003905385,3.127726e-7,0.00001967625,0.03289512,0.08762392],"study_design_scores_gemma":[0.002118993,0.0002352904,0.00001494791,0.5980982,0.02286087,0.00001730168,0.000001612625,0.0001732003,0.000002545657,0.000001805961,0.3761827,0.0002925439],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006300891,0.9713268,0.0002289771,0.002239954,0.002933802,0.02261985,0.0004810469,0.00005674604,0.0001064952],"genre_scores_gemma":[0.000008535537,0.9696419,0.0004474233,0.00707969,0.00119772,0.01850068,0.0002009809,0.0001952327,0.002727807],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3432875,"threshold_uncertainty_score":0.9997473,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2529738115","doi":"10.1016/j.cllc.2016.09.002","title":"Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre","funders":"ImmunoGen","keywords":"Carboplatin; Medicine; Etoposide; Internal medicine; Adverse effect; Phases of clinical research; Lung cancer; Gastroenterology; Chemotherapy; Surgery; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.02302611129199081,"gpt":0.3965206617871,"spread":0.3734945504951092,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007082772,0.0003920636,0.0009843373,0.0001724915,0.0001202423,0.0000190414,0.0002875862,0.00008296882,0.00007751091],"category_scores_gemma":[0.0006996221,0.0002016245,0.0001117034,0.0007249568,0.0004616627,0.0001843372,0.0002145388,0.0005972188,0.000001056108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009110695,"about_ca_system_score_gemma":0.001106012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003720379,"about_ca_topic_score_gemma":0.01072918,"domain_scores_codex":[0.9960976,0.0004342225,0.001137319,0.0008444797,0.0008525483,0.0006338887],"domain_scores_gemma":[0.9968776,0.0007436826,0.000577101,0.0006435887,0.0008656226,0.0002924585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008318297,0.004881216,0.9822566,0.0005767235,0.0003246528,0.0001169873,0.001188713,0.0002361587,0.0004243677,0.00001272749,0.0004483189,0.001215277],"study_design_scores_gemma":[0.06630426,0.002032696,0.9237058,0.003519702,0.0005775075,2.98372e-7,0.0005338217,0.002434774,0.0004443793,0.00001057828,0.00008472146,0.0003514659],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902647,0.002475627,0.00002711086,0.002097404,0.0003339101,0.004507214,0.000135464,0.00003347002,0.0001250907],"genre_scores_gemma":[0.9975053,0.0006538969,0.00003771365,0.0003718779,0.000130234,0.0005014447,0.00002019438,0.00007237266,0.0007069557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05855076,"threshold_uncertainty_score":0.8222009,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2735559606","doi":"10.1016/j.cllc.2017.06.021","title":"Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Interstitial lung disease; Common Terminology Criteria for Adverse Events; Confidence interval; Pneumonitis; Odds ratio; Univariate analysis; Radiology; Lung; Usual interstitial pneumonia; Hazard ratio; Internal medicine; Nuclear medicine; Radiation therapy; Multivariate analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.01726548308040903,"gpt":0.3926696811419582,"spread":0.3754041980615492,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002451368,0.0002278532,0.0004957506,0.0001265819,0.00009183562,0.00004930059,0.00009418085,0.0001047246,0.0000655387],"category_scores_gemma":[0.0004860661,0.0001651152,0.0001419434,0.00008152797,0.0001195748,0.0002730112,0.00002014472,0.0002265216,0.000001683577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007153302,"about_ca_system_score_gemma":0.0002437663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004428754,"about_ca_topic_score_gemma":0.00004595218,"domain_scores_codex":[0.998379,0.0002105753,0.0004791238,0.0003945389,0.0003172666,0.0002195081],"domain_scores_gemma":[0.9982153,0.0003822716,0.0005179169,0.0004780118,0.0001284065,0.0002780928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007158986,0.0007272122,0.9684799,0.0000804912,0.0004660138,0.0000284053,0.00009047808,0.00004801292,0.00001229043,0.000005570455,0.0002458794,0.02265674],"study_design_scores_gemma":[0.01401408,0.003563708,0.9740746,0.0003689118,0.0002969415,6.765468e-7,0.000002096504,0.007480511,0.00003118201,0.000002016071,0.00001320913,0.0001520417],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99687,0.0007439087,0.000005845301,0.0003270804,0.0003181894,0.001449814,0.00009845976,0.00002519258,0.0001614585],"genre_scores_gemma":[0.9980955,0.001281039,0.000005929935,0.00008127042,0.0002256816,0.00008846604,0.0001206948,0.00003415636,0.0000673133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0225047,"threshold_uncertainty_score":0.6733201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3093030175","doi":"10.1016/j.cllc.2020.09.013","title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; National Institutes of Health; Clovis Oncology; Exelixis; Eli Lilly and Company; AstraZeneca; Shire; F. Hoffmann-La Roche; Takeda Pharmaceuticals U.S.A.; Neos Therapeutics; Foundation for the National Institutes of Health; Spectrum Pharmaceuticals; Novartis; National Cancer Institute; AbbVie; Merck; University of Colorado; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Oncology; Lung; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.03232496123790799,"gpt":0.4204253364912456,"spread":0.3881003752533376,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002935869,0.0005252517,0.001344386,0.0001529737,0.0001817042,0.00002939426,0.0002528629,0.0001590327,0.000613828],"category_scores_gemma":[0.0002010568,0.000369565,0.000198693,0.0007979174,0.0001378252,0.0001782842,0.0001877069,0.0007375494,0.000005739684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009833346,"about_ca_system_score_gemma":0.001426373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001484327,"about_ca_topic_score_gemma":0.002555526,"domain_scores_codex":[0.9956341,0.0003209796,0.001490255,0.001157335,0.0008210168,0.0005763301],"domain_scores_gemma":[0.9973465,0.0003794191,0.0006283502,0.0005736547,0.0005320462,0.000539988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01727151,0.04433048,0.9134901,0.000503256,0.001190462,0.0001777102,0.01014508,0.0002386775,0.00001413005,0.000002293071,0.005835874,0.006800402],"study_design_scores_gemma":[0.1838577,0.1062275,0.6924773,0.0009244016,0.007132109,6.107192e-7,0.004307491,0.002456891,0.0002176167,0.000001000949,0.001541589,0.0008557735],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873098,0.002235193,0.00002866912,0.0005911804,0.0007892858,0.00805016,0.0006994648,0.00007534114,0.000220943],"genre_scores_gemma":[0.9963714,0.0001273191,0.00007833023,0.000813743,0.000359837,0.001301686,0.000135361,0.00009758574,0.0007147539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2210128,"threshold_uncertainty_score":0.9998756,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2004682614","doi":"10.3816/clc.2006.s.005","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; T790M; Oncology; Internal medicine; Tyrosine kinase; Erlotinib Hydrochloride; Clinical trial; Cancer; Cancer research; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.05832898923244735,"gpt":0.4730369604921097,"spread":0.4147079712596624,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003224524,0.0008048758,0.00408292,0.0004673689,0.0000986707,0.00003207045,0.0002524606,0.0007671128,0.002656503],"category_scores_gemma":[0.0003572723,0.0005390261,0.001856711,0.00106681,0.0003128105,0.0002168758,0.0001035821,0.001277155,0.00001429508],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00429968,"about_ca_system_score_gemma":0.01314064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004449066,"about_ca_topic_score_gemma":0.000791712,"domain_scores_codex":[0.9946561,0.0003308443,0.002943273,0.0009771462,0.0004415838,0.0006510146],"domain_scores_gemma":[0.9960984,0.001197076,0.001305457,0.000603469,0.000354436,0.0004411356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003346909,0.001114184,0.07084663,0.03302899,0.003041939,0.0001383363,0.0001076227,0.00002169545,0.000003021356,0.0000117686,0.07614461,0.8152065],"study_design_scores_gemma":[0.0113029,0.00134429,0.09632686,0.08271405,0.02044276,0.00004942223,0.00002096869,0.0001007776,0.00001466592,0.00001690709,0.7859734,0.001692985],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002442923,0.984683,0.0000103138,0.0002641944,0.001787163,0.003520041,0.006006612,0.0000793771,0.001206362],"genre_scores_gemma":[0.0009416236,0.9893218,0.0003139416,0.0002275815,0.00177958,0.001510326,0.002571439,0.0001790585,0.003154627],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8135135,"threshold_uncertainty_score":0.9997061,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3119577993","doi":"10.1016/j.cllc.2020.12.015","title":"Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada; Bayer; AstraZeneca; Amgen; Pfizer; Merck","keywords":"Medicine; Hazard ratio; Lung cancer; Internal medicine; Oncology; Exon; Confidence interval; Response Evaluation Criteria in Solid Tumors; Cancer research; Mutation; Population; Progressive disease; Chemotherapy; Biology; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.0256231590915165,"gpt":0.3867317670554133,"spread":0.3611086079638968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00130205,0.0001533381,0.0005737189,0.00006326121,0.00004136,0.00001562048,0.00008082822,0.00009385656,0.0003355351],"category_scores_gemma":[0.00121265,0.0001254542,0.0002298697,0.0003921154,0.0002487563,0.00005473193,0.00008558321,0.0002293719,0.000006446724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00011658,"about_ca_system_score_gemma":0.0006793964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002456891,"about_ca_topic_score_gemma":0.00008618279,"domain_scores_codex":[0.9979773,0.0002200187,0.0009566629,0.0003751429,0.0002469452,0.0002239567],"domain_scores_gemma":[0.9984061,0.0005719824,0.0001847178,0.0004025151,0.0002421921,0.000192483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.03358444,0.0003573903,0.1002212,0.000414897,0.0007892078,0.0001737914,0.0006226467,0.00001514086,0.8225474,0.00001917195,0.001041962,0.04021282],"study_design_scores_gemma":[0.005115726,0.0009860775,0.7964616,0.001636019,0.0003987444,0.0000537862,0.0002768217,0.0000636107,0.1715049,0.00003650671,0.02319613,0.0002700464],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788002,0.01322654,0.00002257574,0.00695555,0.0004545238,0.0003623947,0.0000288117,0.00002381078,0.0001255744],"genre_scores_gemma":[0.9941038,0.002212232,0.0006210767,0.002015052,0.0001189618,0.00004168798,0.000004113624,0.00002368907,0.0008593953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6962404,"threshold_uncertainty_score":0.5115872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2205073074","doi":"10.1016/j.cllc.2015.12.009","title":"Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review","year":2015,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario","funders":"Vrije Universiteit Amsterdam; Australian Geographic Society; Varian Medical Systems","keywords":"SABR volatility model; Medicine; Lung cancer; Quality of life (healthcare); Radiation therapy; MEDLINE; Guideline; Population; Stage (stratigraphy); Radiosurgery; Intensive care medicine; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1550721759633743,"gpt":0.5402312895746902,"spread":0.3851591136113159,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003005142,0.0008926414,0.01298422,0.0001226928,0.0000505174,0.00003362031,0.0003675639,0.0005998174,0.0006736242],"category_scores_gemma":[0.001292657,0.0005743669,0.003129062,0.0004160132,0.0001956217,0.0001101852,0.00008035085,0.0006748238,0.00001061028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002839391,"about_ca_system_score_gemma":0.004181826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004584473,"about_ca_topic_score_gemma":0.0001267443,"domain_scores_codex":[0.9914956,0.001221532,0.004806076,0.00113654,0.0007790843,0.0005611549],"domain_scores_gemma":[0.9905315,0.002905619,0.003562921,0.00152527,0.0007775782,0.0006971325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003914394,0.0004181045,0.009668272,0.9411191,0.01269206,0.00001401641,0.00007982094,3.010156e-7,5.650164e-9,0.00002051846,0.01360284,0.02199346],"study_design_scores_gemma":[0.002746254,0.0004354793,0.0004929097,0.7039489,0.03467263,0.000002838423,0.000004611423,0.00002498461,7.289491e-8,0.000002644781,0.2571862,0.0004825355],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005017276,0.9759851,0.00004176573,0.0004871353,0.001294761,0.02027905,0.001674575,0.00005576795,0.0001316423],"genre_scores_gemma":[0.00006824842,0.965789,0.0001769277,0.002070414,0.0009343083,0.02818538,0.0001013653,0.0001835702,0.002490793],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2435833,"threshold_uncertainty_score":0.9996708,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089438932","doi":"10.3816/clc.2010.n.101","title":"A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; CancerCare Manitoba; Juravinski Cancer Centre; Hôpital Notre-Dame; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Adverse effect; Internal medicine; Lung cancer; Vaccination; Pneumonia; Influenza vaccine; Erythema; Gastroenterology; Cancer; Stage (stratigraphy); Surgery; Oncology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.03536635394876456,"gpt":0.3802033103895624,"spread":0.3448369564407978,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001011026,0.0002237886,0.0006744485,0.00009770752,0.0001151706,0.00002164818,0.0007547572,0.0002488169,0.00077879],"category_scores_gemma":[0.0001406404,0.0001435151,0.0000696451,0.0003267256,0.000069589,0.0001875142,0.0003287359,0.0008077886,0.000004275205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007003298,"about_ca_system_score_gemma":0.0004800163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005418135,"about_ca_topic_score_gemma":0.007909573,"domain_scores_codex":[0.9977708,0.0003693019,0.001034266,0.0003759898,0.00008834332,0.0003612728],"domain_scores_gemma":[0.9979265,0.0006720346,0.0004825372,0.0006211973,0.0002604435,0.00003726064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0341675,0.004132643,0.9225906,0.00006077714,0.000581496,6.785461e-7,0.001948036,0.00009847624,0.03167344,0.00001326115,0.0007196112,0.00401347],"study_design_scores_gemma":[0.04625692,0.001743159,0.9381087,0.0002664872,0.0001954176,1.855894e-7,0.0003264631,0.0001409901,0.01070608,0.00000142115,0.002031314,0.0002228089],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993912,0.001331246,0.00009684831,0.0001998688,0.0009715798,0.003311141,0.00007465164,0.00000994282,0.00009276629],"genre_scores_gemma":[0.9938962,0.0001837232,0.0001052314,0.0003127395,0.00003689175,0.0001650455,0.00002119599,0.00003058677,0.005248378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02096736,"threshold_uncertainty_score":0.8527205,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2794061572","doi":"10.1016/j.cllc.2018.03.009","title":"Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Genentech; Ariad Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Medicine; Lung cancer; Lung; Internal medicine; Oncology; Squamous-cell carcinoma of the lung; Erlotinib; Epidermal growth factor receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0457708610967405,"gpt":0.4460203423078012,"spread":0.4002494812110607,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005684334,0.0006623168,0.002003557,0.0001955252,0.0003773757,0.00004920275,0.0002541055,0.0003258778,0.0007198806],"category_scores_gemma":[0.0003311881,0.00040243,0.0006409596,0.0006770638,0.0006829939,0.0002105765,0.0001057207,0.000293471,0.000004173538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009603305,"about_ca_system_score_gemma":0.001340074,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004525938,"about_ca_topic_score_gemma":0.001710684,"domain_scores_codex":[0.9951231,0.0003908002,0.002131783,0.001019503,0.0007307102,0.0006040696],"domain_scores_gemma":[0.9941978,0.001624161,0.001722867,0.0008627772,0.001186271,0.0004061098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002466646,0.002514362,0.9734918,0.0008384589,0.006286161,0.00002316021,0.00331453,0.0003886212,0.0002138305,0.00003245663,0.003986261,0.006443717],"study_design_scores_gemma":[0.03964771,0.004235163,0.9013645,0.003594035,0.02820925,0.000007891779,0.0004207115,0.01015277,0.01088281,0.00002704549,0.0007159133,0.0007422218],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768361,0.01264689,0.0005124242,0.001021813,0.001258528,0.005307553,0.0009424391,0.00005074289,0.001423527],"genre_scores_gemma":[0.9911213,0.003628108,0.00059434,0.0005462612,0.0009561,0.00087094,0.0002735268,0.0001057326,0.001903723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07212732,"threshold_uncertainty_score":0.9998428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2885210084","doi":"10.1016/j.cllc.2018.07.008","title":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Infection and Immunity; Clovis Oncology","keywords":"T790M; Liquid biopsy; Lung cancer; Medicine; Cancer research; KRAS; Cell-free fetal DNA; DNA sequencing; Resistance mutation; Oncology; Gene; Osimertinib; Exon; EGFR inhibitors; Internal medicine; Epidermal growth factor receptor; Gefitinib; Cancer; Polymerase chain reaction; Erlotinib; Biology; Genetics; Reverse transcriptase; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0895180354257775,"gpt":0.3965163339387146,"spread":0.3069982985129371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005753714,0.0001319917,0.0002707923,0.00008197925,0.0001467247,0.00002857745,0.00006114053,0.0001393596,0.00006641916],"category_scores_gemma":[0.0005130312,0.0001135725,0.00007018286,0.0002103899,0.0001310526,0.0001631522,0.00004024666,0.0001206384,0.000006676825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004290177,"about_ca_system_score_gemma":0.0005553008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000722589,"about_ca_topic_score_gemma":0.0005024044,"domain_scores_codex":[0.9984698,0.0001353733,0.000582709,0.0004015937,0.0002428471,0.0001676899],"domain_scores_gemma":[0.9987464,0.0001361074,0.0001636809,0.0003995028,0.0003656624,0.0001886487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003171002,0.0002284349,0.04366793,0.0001799027,0.0002352866,0.000009746641,0.001856824,0.0000393238,0.6805011,0.0002502719,0.2660965,0.00376365],"study_design_scores_gemma":[0.02203538,0.008432309,0.3643463,0.002224918,0.00375686,0.00002088364,0.0007037878,0.02401647,0.5049332,0.0003925288,0.06815369,0.0009836985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904194,0.001514757,0.0009049629,0.003540751,0.001280359,0.0007433933,0.0001251756,0.00005055203,0.001420612],"genre_scores_gemma":[0.9878961,0.000252793,0.004038038,0.00123544,0.002970711,0.0001250022,0.00004958202,0.00002390786,0.003408356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3206783,"threshold_uncertainty_score":0.4631352,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2010808964","doi":"10.3816/clc.2004.n.030","title":"Clinical Benefit of Zoledronic Acid in Patients with Lung Cancer and OtherSolid Tumors: Analysis Based on History of Skeletal Complications","year":2004,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Zoledronic acid; Placebo; Internal medicine; Lung cancer; Spinal cord compression; Surgery; Pathologic fracture; Odds ratio; Urology; Pathology; Spinal cord","retraction":null,"screen_n_in":null,"score":{"opus":0.02701892740615797,"gpt":0.3890881316739154,"spread":0.3620692042677575,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002748933,0.0001575226,0.0008747631,0.0001657511,0.00002187049,0.000001545647,0.00007453456,0.0001410476,0.0001231604],"category_scores_gemma":[0.00007238672,0.0001220217,0.0002195671,0.0003198824,0.000306783,0.00003579252,0.00001725565,0.0003073586,0.000001198183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007749476,"about_ca_system_score_gemma":0.001085236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001599106,"about_ca_topic_score_gemma":0.002129359,"domain_scores_codex":[0.9979896,0.0000591694,0.001043817,0.0004082218,0.0002668861,0.0002322895],"domain_scores_gemma":[0.998503,0.0002172338,0.0004429024,0.0004131943,0.0001667866,0.0002568772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001041438,0.001670923,0.9909067,0.0001874261,0.0005501463,0.000002766645,0.00004606371,0.0006190649,0.000001025726,0.00003498149,0.0001249581,0.004814512],"study_design_scores_gemma":[0.01102629,0.0009572703,0.9833836,0.0006451074,0.001358834,1.376017e-7,0.000003634116,0.002332666,0.000005811351,0.000008514945,0.0001777298,0.000100393],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953259,0.002635032,0.00005574543,0.0006922072,0.0001412558,0.000652746,0.0001006293,0.00001363449,0.0003828265],"genre_scores_gemma":[0.9977462,0.0002705922,0.0004201091,0.001220922,0.00003934425,0.0001056417,0.00004777361,0.00002092707,0.0001284678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009984855,"threshold_uncertainty_score":0.49759,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035891246","doi":"10.1016/j.cllc.2013.11.003","title":"Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis","year":2013,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Chemotherapy; Regimen; Internal medicine; Lung cancer; Chemotherapy regimen; Oncology; Multivariate analysis; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.05580052204856029,"gpt":0.4771340842461771,"spread":0.4213335621976169,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000741625,0.0002687885,0.0008865939,0.0003212287,0.00006728342,0.00006242675,0.0004453967,0.0002045058,0.004841552],"category_scores_gemma":[0.000238657,0.0002158832,0.0003872534,0.0008939971,0.0002134609,0.0002404831,0.0001513014,0.0007570311,0.00003306089],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008082144,"about_ca_system_score_gemma":0.0005305035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006455987,"about_ca_topic_score_gemma":0.004746887,"domain_scores_codex":[0.9971186,0.0001420586,0.0009072121,0.0007729892,0.0005021744,0.000556945],"domain_scores_gemma":[0.997992,0.0003092255,0.0002062299,0.0006238056,0.0004760762,0.0003926854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003691519,0.0004878277,0.9646021,0.0001322804,0.002091434,0.00001909911,0.0002568806,0.000300413,0.0002140559,0.00002078803,0.01565433,0.0158516],"study_design_scores_gemma":[0.005227463,0.0002460429,0.9201068,0.0002243714,0.0009568632,9.801987e-7,0.00008733952,0.06544676,0.0003020248,0.00004961829,0.007041137,0.0003105526],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.969398,0.006431904,0.0001561542,0.01712619,0.000905522,0.001275441,0.00005222143,0.0001043966,0.004550138],"genre_scores_gemma":[0.9577634,0.0240789,0.0007520388,0.005912779,0.002082508,0.001112706,0.00006187791,0.00006023522,0.008175582],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06514635,"threshold_uncertainty_score":0.9960682,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2529324715","doi":"10.1016/j.cllc.2016.09.008","title":"Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Lean body mass; Lung cancer; Pharmacokinetics; Kilogram; Vinorelbine; Internal medicine; Urology; Pemetrexed; Common Terminology Criteria for Adverse Events; Body surface area; Toxicity; Nuclear medicine; Cancer; Surgery; Chemotherapy; Body weight","retraction":null,"screen_n_in":null,"score":{"opus":0.03719130144166376,"gpt":0.4061193345851192,"spread":0.3689280331434555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006660541,0.0003751738,0.001097553,0.0001189028,0.0001024072,0.0000209704,0.0002593868,0.0003914686,0.002420133],"category_scores_gemma":[0.0001513718,0.0002692524,0.0002581533,0.0002489956,0.0001958058,0.0001189264,0.00006872208,0.0008232005,0.0000296669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006674521,"about_ca_system_score_gemma":0.000578907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007937158,"about_ca_topic_score_gemma":0.001025689,"domain_scores_codex":[0.9965004,0.0001390056,0.001279779,0.0009328761,0.000369696,0.0007782776],"domain_scores_gemma":[0.9975674,0.0007087729,0.0003713724,0.0006049382,0.0001833471,0.0005641877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001516202,0.0005704943,0.9661019,0.0006794865,0.00009830575,0.00006287856,0.0002420684,0.00001150805,0.007771545,0.00003040684,0.01598225,0.006932893],"study_design_scores_gemma":[0.06280091,0.000573863,0.8751209,0.00932457,0.0004951679,0.000009627682,0.0002431871,0.008282352,0.01195839,0.0009332208,0.02897844,0.001279363],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.969504,0.005411099,0.0003183272,0.01971756,0.001711756,0.001781465,0.0001221944,0.0001829989,0.001250578],"genre_scores_gemma":[0.9675111,0.008891774,0.002939567,0.01625738,0.001273852,0.0005806473,0.00003156585,0.00007878897,0.002435332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09098105,"threshold_uncertainty_score":0.999976,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101440707","doi":"10.1016/j.cllc.2015.05.010","title":"A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada); Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University Health Centre; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Adverse effect; Hazard ratio; Chemotherapy; Randomized controlled trial; Confidence interval; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.08825096488267198,"gpt":0.4698113163662173,"spread":0.3815603514835453,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009513784,0.0004040938,0.001988786,0.0002514771,0.00008101853,0.00004678472,0.0001478185,0.0001555217,0.0001289911],"category_scores_gemma":[0.00009110441,0.0002640594,0.0001248671,0.0004665224,0.000201687,0.0001880686,0.00003196999,0.000197211,3.067788e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001185615,"about_ca_system_score_gemma":0.002327751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003548024,"about_ca_topic_score_gemma":0.01267785,"domain_scores_codex":[0.9972593,0.0002185924,0.001170893,0.0006734213,0.0003170641,0.0003606853],"domain_scores_gemma":[0.9976923,0.0006378703,0.0005683383,0.0003728335,0.0004272081,0.000301435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9455742,0.01134051,0.0254627,0.0001543934,0.001463787,0.00002063745,0.002654409,0.0001987275,0.0001183416,0.00002140322,0.0005262179,0.01246466],"study_design_scores_gemma":[0.9473722,0.02637018,0.0007229449,0.0006465221,0.001466912,0.000001836864,0.0002948113,0.02092449,0.0009861811,0.00006112944,0.0008544787,0.0002983111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787045,0.004274023,0.0005256634,0.001365905,0.0003009709,0.01422191,0.000279909,0.00002482374,0.0003022704],"genre_scores_gemma":[0.9850707,0.002303106,0.002792266,0.0005311354,0.0001531271,0.00653485,0.0001636237,0.00008372777,0.002367438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02473976,"threshold_uncertainty_score":0.9999812,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075136921","doi":"10.1016/j.cllc.2011.03.028","title":"Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Lung; Radiology; Carcinoma; Oncology; Small Cell Lung Carcinoma; Internal medicine; Small-cell carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.09780638833724518,"gpt":0.4554487585161819,"spread":0.3576423701789367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000806184,0.0004107059,0.001762002,0.0001275529,0.00009222943,0.00001142659,0.0002901631,0.0002667388,0.0006296216],"category_scores_gemma":[0.0006665366,0.0002671379,0.0004806675,0.0003235614,0.001216898,0.0000988873,0.0001420907,0.0008016597,0.000009970966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003117395,"about_ca_system_score_gemma":0.0007667902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007358324,"about_ca_topic_score_gemma":0.0001462267,"domain_scores_codex":[0.9960095,0.0005178978,0.001442153,0.000851321,0.0005649801,0.0006141735],"domain_scores_gemma":[0.9953498,0.001363516,0.0006632529,0.0008167458,0.001320564,0.0004860969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005461824,0.001241879,0.9827073,0.0003907331,0.001804288,0.00009952801,0.0007594753,9.900923e-7,0.00001561967,0.00001386149,0.003848537,0.003655923],"study_design_scores_gemma":[0.008803625,0.003161622,0.9847345,0.000307692,0.0008564679,0.000001257426,0.0001985851,0.0001560168,0.0007549256,0.000004335494,0.0007211078,0.0002998843],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901227,0.002991702,0.0001069922,0.0002072863,0.0004114273,0.002141498,0.0002062542,0.00007542071,0.003736668],"genre_scores_gemma":[0.9895973,0.002753293,0.001694814,0.001191198,0.0002481744,0.0002062018,0.00002985782,0.0000871412,0.004192021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003356038,"threshold_uncertainty_score":0.9999781,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2046653378","doi":"10.3816/clc.2003.n.003","title":"Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer","year":2003,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario; Jewish General Hospital; McGill University; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Lung cancer; Adverse effect; Nausea; Internal medicine; Gastroenterology; Vomiting; Toxicity; Phases of clinical research","retraction":null,"screen_n_in":null,"score":{"opus":0.02456018373456367,"gpt":0.3771726373027213,"spread":0.3526124535681577,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005037292,0.0001680453,0.000485713,0.00002268974,0.00005020677,0.000004012124,0.0002090713,0.0001664921,0.00004147001],"category_scores_gemma":[0.0001233914,0.0001006965,0.0003151877,0.0001440242,0.0002834053,0.000002682391,0.00004632642,0.0001131318,8.326283e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002824856,"about_ca_system_score_gemma":0.0004622641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002960782,"about_ca_topic_score_gemma":0.0005413364,"domain_scores_codex":[0.9983469,0.0002439535,0.0007355117,0.0003212609,0.0001468966,0.0002054829],"domain_scores_gemma":[0.9988409,0.000155092,0.0003546109,0.0005067171,0.00008368651,0.00005900779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1341454,0.03569693,0.06524471,0.001056221,0.002586433,0.000005529491,0.006459495,0.001395264,0.3539816,0.000508059,0.01685812,0.3820622],"study_design_scores_gemma":[0.3020611,0.00903832,0.02663371,0.0002798924,0.001816481,0.000003589154,0.0002977928,0.0003176638,0.2108102,0.0000332062,0.4481198,0.0005882554],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9722952,0.02437357,0.00003733561,0.0001513062,0.00140373,0.00102656,0.0001377281,0.000001593172,0.0005729616],"genre_scores_gemma":[0.9580904,0.04014233,0.00006869093,0.0001733663,0.000767367,0.0001006294,0.000009427524,0.00001694356,0.0006309013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4312617,"threshold_uncertainty_score":0.4106283,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105133481","doi":"10.3816/clc.2009.n.045","title":"Understanding Prognostic Gene Expression Signatures in Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lung cancer; Gene expression profiling; Gene signature; Medicine; Gene expression; DNA microarray; Computational biology; Bioinformatics; Microarray; Oncology; Gene; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.1454417708597023,"gpt":0.4586356216586567,"spread":0.3131938507989545,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004681379,0.0005158026,0.00117221,0.000157438,0.00009905,0.00005422267,0.0005219693,0.001261379,0.0002031323],"category_scores_gemma":[0.0002082725,0.0004156881,0.0005691048,0.0003427788,0.0001051069,0.000007598145,0.0001644464,0.0007913588,0.000003127535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004169766,"about_ca_system_score_gemma":0.001066311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001157427,"about_ca_topic_score_gemma":0.00007075319,"domain_scores_codex":[0.9964569,0.0004295035,0.001153784,0.001195935,0.0002864329,0.0004774595],"domain_scores_gemma":[0.9982894,0.0001207901,0.0006287703,0.0006706582,0.00007412119,0.0002162615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002295741,0.0004195174,0.005192674,0.009754229,0.0004670936,0.00002788537,0.00004174143,0.0004110687,0.002462385,0.00008184993,0.3005061,0.6804059],"study_design_scores_gemma":[0.0006900411,0.00009286063,0.0003207927,0.01596215,0.0005600214,0.000001887374,0.00001191891,0.0001509762,0.0003223652,0.000031514,0.9811321,0.0007233786],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009648263,0.9957113,0.0007782017,0.0001152639,0.001403455,0.001264605,0.00007485275,0.00002939103,0.0005264522],"genre_scores_gemma":[0.001598782,0.99349,0.0001473188,0.0003683335,0.001742326,0.0009135533,0.0002412228,0.00008358071,0.001414845],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.680626,"threshold_uncertainty_score":0.9998295,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2809572377","doi":"10.1016/j.cllc.2018.06.001","title":"Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung; Radiosurgery; Radiation therapy; Cohort; Toxicity; Esophagus; Internal medicine; Radiology","retraction":null,"screen_n_in":null,"score":{"opus":0.03524032200445824,"gpt":0.3937644911359875,"spread":0.3585241691315292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001133277,0.0002269152,0.0004632796,0.00004193875,0.0001192888,0.00003763588,0.00008899326,0.0001097911,0.0007677422],"category_scores_gemma":[0.00005295951,0.0001499837,0.0001367557,0.0002246359,0.0005221257,0.0001429109,0.00001243282,0.0001853497,0.00002397264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000813232,"about_ca_system_score_gemma":0.0003028186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002376443,"about_ca_topic_score_gemma":0.000157983,"domain_scores_codex":[0.9983013,0.00005917838,0.0004445562,0.0005423058,0.0002720172,0.000380595],"domain_scores_gemma":[0.9988487,0.0001144948,0.0001591878,0.0004107486,0.0001602359,0.0003065863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001602054,0.0009306935,0.9885194,0.00005298282,0.0004186824,0.0001196839,0.0002934131,0.000002635714,0.0004116593,0.00005645006,0.001906637,0.005685763],"study_design_scores_gemma":[0.00855469,0.005182427,0.9589619,0.001353472,0.0007575204,0.0000906127,0.00006343215,0.0006952136,0.008173794,0.000003729532,0.01579728,0.0003659381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936641,0.001499342,0.0001230866,0.001282586,0.0005766171,0.0007286304,0.00001193447,0.0001259004,0.001987729],"genre_scores_gemma":[0.995015,0.000743679,0.0003203512,0.001571665,0.001342459,0.0002026381,0.00001216011,0.0000342798,0.0007577684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02955745,"threshold_uncertainty_score":0.8406239,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3166324988","doi":"10.1016/j.cllc.2021.05.009","title":"Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"Genentech; Daiichi-Sankyo; Merck KGaA; Moffitt Cancer Center; Takeda Pharmaceuticals U.S.A.; Spectrum Pharmaceuticals; Sanofi; Novartis; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01887738721131567,"gpt":0.3471904455025281,"spread":0.3283130582912124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004492147,0.0003946904,0.0009814274,0.00009517416,0.00007594133,0.0000679329,0.000197141,0.0002906533,0.005227425],"category_scores_gemma":[0.00003388811,0.0003157662,0.0003028083,0.0005992274,0.0002209747,0.0001307478,0.00005948053,0.0007062276,0.000005948883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007874605,"about_ca_system_score_gemma":0.001586292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009950176,"about_ca_topic_score_gemma":0.002424817,"domain_scores_codex":[0.9967985,0.0001435867,0.0009645513,0.0008911364,0.000529075,0.0006732229],"domain_scores_gemma":[0.9982782,0.0001810412,0.0002717517,0.0006329213,0.0003516051,0.0002844668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00938936,0.001041082,0.9519863,0.0005732392,0.0005093963,0.0001386958,0.0004249018,0.00002458332,0.0004606717,0.000002240373,0.007668559,0.02778095],"study_design_scores_gemma":[0.05247441,0.001175423,0.8695996,0.002299591,0.0004634723,0.000004095433,0.0002345683,0.001386343,0.002793924,0.000001964702,0.068721,0.0008455887],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9672751,0.02659239,0.0001187728,0.00104744,0.001694346,0.001378116,0.0001720657,0.00005001611,0.001671783],"genre_scores_gemma":[0.9726806,0.008925749,0.0001980272,0.002674429,0.0005894432,0.0007327486,0.00008162842,0.000102152,0.01401517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08238671,"threshold_uncertainty_score":0.9999294,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905706267","doi":"10.1016/j.cllc.2018.12.010","title":"Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Care Ontario","keywords":"Medicine; Logistic regression; Lung cancer; Confidence interval; Odds ratio; Cohort; Medicaid; Health care; Quality of life (healthcare); Demography; Internal medicine; Finance; Emergency medicine; Family medicine; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.02366015001680178,"gpt":0.319641527852575,"spread":0.2959813778357732,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000789238,0.0003707169,0.001278314,0.0002438402,0.0002209678,0.0001385205,0.0005166702,0.0003840247,0.0007212864],"category_scores_gemma":[0.000262361,0.0003729142,0.0002186504,0.0004769519,0.000390807,0.0005779171,0.0001327845,0.0005632768,0.00008285669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002123127,"about_ca_system_score_gemma":0.0008551409,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007503862,"about_ca_topic_score_gemma":0.01487829,"domain_scores_codex":[0.995901,0.00005750428,0.001914621,0.001072603,0.0001048465,0.0009494605],"domain_scores_gemma":[0.9975434,0.00009833918,0.001105553,0.000591165,0.0002880235,0.0003735206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002997905,0.00007957037,0.9653654,0.0002227483,0.00008139263,0.000002698347,0.0006972656,0.00007364282,3.858286e-8,0.008736225,0.01420392,0.01023727],"study_design_scores_gemma":[0.003465638,0.0003908515,0.9573348,0.0005087074,0.00002233557,2.615026e-7,0.0000714749,0.002086211,9.472945e-7,0.0001598977,0.03540839,0.0005505126],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648476,0.01181362,0.0005836032,0.002179494,0.00394331,0.001474687,0.001241611,0.00012333,0.01379274],"genre_scores_gemma":[0.9935028,0.0006274029,0.0001777379,0.001945993,0.002484004,0.0003463301,0.00003345289,0.00007846345,0.0008038324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02865518,"threshold_uncertainty_score":0.9998723,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2753686261","doi":"10.1016/j.cllc.2017.08.002","title":"Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Lung; Radiation therapy; Radiosurgery; Stereotactic radiotherapy; Radiology; Internal medicine; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.04554200722388401,"gpt":0.4745003899239481,"spread":0.4289583827000641,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006143539,0.0002641551,0.001162688,0.00004746304,0.0001783329,0.00006434682,0.0002418829,0.0001785005,0.0004028769],"category_scores_gemma":[0.0002525774,0.000188543,0.001565985,0.00006450292,0.0001557934,0.0001687524,0.00006904556,0.0002930533,0.00000685539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008539445,"about_ca_system_score_gemma":0.000619932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001556611,"about_ca_topic_score_gemma":0.00004804021,"domain_scores_codex":[0.9979798,0.0001178642,0.0006578431,0.0004894721,0.0003711716,0.0003838727],"domain_scores_gemma":[0.9974301,0.0004366553,0.0004417986,0.001245092,0.0001115471,0.0003347834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006070378,0.0004140109,0.9751009,0.0001294115,0.004880148,0.00004883247,0.00006927946,0.000004509231,0.000167264,0.0000229533,0.007859848,0.01069586],"study_design_scores_gemma":[0.004824866,0.0006811354,0.9895881,0.0005770312,0.001567248,0.000001749051,0.000006501366,0.0004050013,0.0001401846,0.000009742208,0.002006337,0.0001921328],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784004,0.01331824,0.000007927723,0.001189901,0.003660237,0.0008103935,0.00006647468,0.00004031698,0.002506124],"genre_scores_gemma":[0.990534,0.006857057,0.0001039941,0.0001743842,0.001336241,0.0001150248,0.00001260752,0.00005435395,0.000812326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01448722,"threshold_uncertainty_score":0.7688562,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2067441207","doi":"10.3816/clc.2009.n.027","title":"PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Cisplatin; Etoposide; Oncology; Radiation therapy; Chemotherapy; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02002691147596779,"gpt":0.3700348425778369,"spread":0.3500079311018691,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434753,0.0005216592,0.001608217,0.0002902439,0.00009240012,0.0000214405,0.0001666532,0.0003783252,0.0001383172],"category_scores_gemma":[0.0001329134,0.0004647359,0.0001940317,0.0005720536,0.0002105147,0.0002341302,0.00002462718,0.0003207712,2.36076e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005316324,"about_ca_system_score_gemma":0.00051575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002291603,"about_ca_topic_score_gemma":0.001184267,"domain_scores_codex":[0.9959382,0.0003268743,0.001897297,0.0009266657,0.0004883346,0.0004226113],"domain_scores_gemma":[0.9959379,0.001125707,0.001873664,0.0005088449,0.0003503136,0.0002035007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04833825,0.0124001,0.7193763,0.0005440153,0.0008775683,0.000009410599,0.003949638,0.0001981064,0.1328296,0.000008017916,0.005926594,0.07554243],"study_design_scores_gemma":[0.520339,0.02774132,0.1752237,0.0007151741,0.001670822,0.000002295428,0.000748178,0.01079075,0.2603635,0.000009304777,0.00139136,0.001004647],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9664489,0.02585596,0.0001693791,0.0004403726,0.0003706406,0.006352869,0.0001880739,0.00003136703,0.000142434],"genre_scores_gemma":[0.9796948,0.01840911,0.0001592482,0.0004215298,0.00009031528,0.0007133959,0.0001369928,0.0000683603,0.0003062711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5441526,"threshold_uncertainty_score":0.9997804,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2042273751","doi":"10.3816/clc.2004.n.010","title":"Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy","year":2004,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Tomotherapy; Medicine; Contouring; Radiation therapy; Radiology; Radiation treatment planning; Lung cancer; Nuclear medicine; Medical physics; Mediastinum; Image-guided radiation therapy; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.009551831587050483,"gpt":0.3685170852425558,"spread":0.3589652536555053,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002596659,0.0001383714,0.0002351595,0.00004553314,0.0000798441,0.00003019737,0.0001821408,0.00003891414,0.00004782481],"category_scores_gemma":[0.000006708568,0.00009962993,0.0001622477,0.0001766378,0.0001351238,0.0001182152,0.00004460856,0.00017352,3.948633e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003668105,"about_ca_system_score_gemma":0.00009144527,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002632285,"about_ca_topic_score_gemma":0.000002580518,"domain_scores_codex":[0.9989487,0.00005554356,0.0004202396,0.0002784218,0.0001229197,0.0001741859],"domain_scores_gemma":[0.9992811,0.0001029756,0.0001781067,0.0002754423,0.00009805337,0.00006432349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0001902979,0.0001256346,0.09791585,0.0000106387,0.0002034309,0.000001116548,0.0001626628,0.0005615818,0.009111608,0.0009514281,0.001355433,0.8894103],"study_design_scores_gemma":[0.01226272,0.001776239,0.5970778,0.0006841196,0.0005916015,0.000005398678,0.00028992,0.02812697,0.1730781,0.02750245,0.1559045,0.002700226],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.648067,0.003213003,0.3461727,0.001011354,0.000373781,0.0008711215,0.00006960742,0.00007542355,0.0001459586],"genre_scores_gemma":[0.9846912,0.000402718,0.01306188,0.001043676,0.0006267609,0.00009520724,0.000007554536,0.00002565587,0.00004536079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8867101,"threshold_uncertainty_score":0.4062791,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967197142","doi":"10.3816/clc.2009.n.024","title":"Management and Prognosis in Synchronous Solitary Resected Brain Metastasis from Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Brain metastasis; Lung cancer; Radiation therapy; Craniotomy; Univariate analysis; Stage (stratigraphy); Metastasis; Surgery; Performance status; Chemotherapy; Internal medicine; Oncology; Cancer; Radiology; Multivariate analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.02925830588355858,"gpt":0.3787964857123529,"spread":0.3495381798287943,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005466784,0.000321304,0.0008090312,0.0001288331,0.00007489679,0.00003216283,0.0001373257,0.0001739279,0.0004907201],"category_scores_gemma":[0.00006609598,0.0002609417,0.0002250479,0.0003207252,0.0001030963,0.00007110853,0.00009888713,0.0004298505,0.00000627734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003525116,"about_ca_system_score_gemma":0.0001493403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001843782,"about_ca_topic_score_gemma":0.0008979524,"domain_scores_codex":[0.997358,0.0001972405,0.0007960349,0.0008405249,0.0002841577,0.0005239928],"domain_scores_gemma":[0.9985839,0.0004066816,0.0001557202,0.0004373146,0.00006815371,0.0003482329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001201578,0.002172727,0.6933975,0.0005613412,0.001945561,0.00140257,0.0003080381,0.00009330892,0.0001155081,0.00004526195,0.04742305,0.2513336],"study_design_scores_gemma":[0.009198292,0.000801947,0.9766133,0.001065295,0.002727369,0.00000572535,0.0001268877,0.005035385,0.000314125,0.0001277157,0.003602148,0.0003817385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9453515,0.03515724,0.0001460858,0.01579279,0.0003520556,0.002123075,0.000203662,0.00006701094,0.0008065957],"genre_scores_gemma":[0.9752418,0.009014882,0.006289364,0.007241192,0.0004801642,0.0005948771,0.0001115168,0.0000445577,0.000981666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2832159,"threshold_uncertainty_score":0.9999843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528163604","doi":"10.1016/j.cllc.2016.08.002","title":"Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Dalhousie University; NOSM University; University of British Columbia; Queen's University; Western University; McGill University Health Centre; University of Calgary; CancerCare Manitoba; Windsor Regional Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta; University of Saskatchewan; Ontario Clinical Oncology Group; Saint John Regional Hospital; Hôpital Notre-Dame; McMaster University","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Radiation therapy; Oncology; Randomized controlled trial; Clinical trial; Internal medicine; Radiology; Medical physics","retraction":null,"screen_n_in":null,"score":{"opus":0.08825697473841296,"gpt":0.4630623146222363,"spread":0.3748053398838234,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004789015,0.0004103907,0.002097285,0.0001158713,0.0002765167,0.00004659541,0.0002482614,0.0005592113,0.002347674],"category_scores_gemma":[0.001052709,0.0002349403,0.0009408013,0.0001230634,0.0005232283,0.0001744544,0.00002313975,0.0004338612,7.615556e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00344702,"about_ca_system_score_gemma":0.01364634,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.04934062,"about_ca_topic_score_gemma":0.148108,"domain_scores_codex":[0.994947,0.0007596068,0.002443537,0.0008504377,0.0004447703,0.0005547199],"domain_scores_gemma":[0.9783364,0.01886819,0.001145869,0.0004579561,0.0005703536,0.0006212216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9447825,0.003062222,0.002758614,0.0001901782,0.005691384,0.00001007984,0.0001206122,0.00002142102,0.00005603513,0.0001311742,0.022009,0.02116678],"study_design_scores_gemma":[0.8063425,0.01224513,0.0004084521,0.0002798675,0.002274749,0.000001786662,0.00001250216,0.004481685,0.00005159347,0.00002235181,0.1736438,0.0002355522],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1681,0.003699037,0.03527325,0.04027513,0.01179518,0.7395096,0.001000495,0.00008201157,0.0002652893],"genre_scores_gemma":[0.03309916,0.007641753,0.006551718,0.004854279,0.006772268,0.9262313,0.0001793032,0.000169443,0.01450078],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.1867217,"threshold_uncertainty_score":0.9985643,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2019875881","doi":"10.1016/j.cllc.2012.04.003","title":"A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Rash; Nausea; Neutropenia; Lung cancer; Adverse effect; Pharmacokinetics; Internal medicine; Phases of clinical research; Oncology; Response Evaluation Criteria in Solid Tumors; Pharmacology; Toxicity; Chemotherapy; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.04642812213176898,"gpt":0.4313785693585379,"spread":0.3849504472267689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003378038,0.0003381626,0.0008709744,0.0001486924,0.00008042403,0.00002729856,0.0001900401,0.0001489056,0.0002924219],"category_scores_gemma":[0.00003768018,0.0002198762,0.0000563363,0.0006831106,0.0000953788,0.0002579349,0.00007049303,0.0003250872,0.000003434911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005686824,"about_ca_system_score_gemma":0.0006140143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00451694,"about_ca_topic_score_gemma":0.004578022,"domain_scores_codex":[0.9975462,0.000155915,0.0008535454,0.0005508651,0.0003821373,0.0005113221],"domain_scores_gemma":[0.9981916,0.0001610975,0.000466594,0.0004921324,0.0003568875,0.0003317033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004751878,0.03877852,0.9285477,0.0001996804,0.001073293,0.0000149526,0.004078472,0.00007312602,0.00003440313,0.000002162251,0.0004354031,0.02201042],"study_design_scores_gemma":[0.1133864,0.01040192,0.8692917,0.0009247245,0.004127778,0.000001119653,0.000449994,0.0008164833,0.0001076104,9.894527e-7,0.0001561323,0.0003351496],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896256,0.001742215,0.00005084054,0.0001157866,0.0002732799,0.006993418,0.00007530844,0.00003471335,0.001088862],"genre_scores_gemma":[0.9960698,0.0002366253,0.0004410938,0.0002628372,0.0001940933,0.001542065,0.00009678562,0.00008110816,0.001075597],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1086346,"threshold_uncertainty_score":0.8966289,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012503365","doi":"10.1016/j.cllc.2011.11.010","title":"Delay Between the Initial Symptoms, the Diagnosis and the Onset of Specific Treatment in Elderly Patients With Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Medicine; Lung cancer; Cancer; Lung; Internal medicine; Surgery; Pediatrics","retraction":null,"screen_n_in":null,"score":{"opus":0.0431387002219345,"gpt":0.421283475776395,"spread":0.3781447755544605,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003763704,0.0001961314,0.0004611044,0.00003203303,0.0001619048,0.00001969355,0.0001231172,0.00008920436,0.0001779956],"category_scores_gemma":[0.00005323275,0.00007263411,0.0001281345,0.0002029599,0.0005769219,0.00008175128,0.00004030309,0.0002501072,0.000001851415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002972935,"about_ca_system_score_gemma":0.0002643773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001716833,"about_ca_topic_score_gemma":0.0009262611,"domain_scores_codex":[0.9984394,0.0002340456,0.0005130881,0.0002392888,0.0002659891,0.0003081402],"domain_scores_gemma":[0.9974421,0.001730743,0.0002113674,0.000392687,0.00009878975,0.000124372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005735347,0.0003384569,0.9498346,0.00002291934,0.0009261855,0.000001979779,0.001433191,0.000008972368,6.938596e-8,0.0000723011,0.002333269,0.04445445],"study_design_scores_gemma":[0.009213221,0.0004329763,0.978911,0.0002343887,0.002144919,0.000001383704,0.0001039874,0.00002952258,0.00001484981,0.0000180276,0.008798534,0.00009719656],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740043,0.01714037,0.000008570565,0.005552793,0.0004188108,0.002142666,0.0002466381,0.00001175745,0.0004741285],"genre_scores_gemma":[0.9920508,0.004707104,0.00002040813,0.000709003,0.0006621883,0.00164611,0.0000367895,0.00002487649,0.0001427367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04435725,"threshold_uncertainty_score":0.2961933,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145963430","doi":"10.1016/j.cllc.2014.04.008","title":"Brain Metastases in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; McMaster University; CancerCare Manitoba","funders":"","keywords":"Medicine; Radiosurgery; Lung cancer; Radiation therapy; Intensive care medicine; Brain metastasis; Oncology; Stereotactic radiotherapy; Cancer; Internal medicine; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.08575874932576812,"gpt":0.4787013213386106,"spread":0.3929425720128425,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00200054,0.0009131525,0.00561033,0.0002634114,0.00007147351,0.00004490704,0.000383012,0.0007460752,0.002134758],"category_scores_gemma":[0.000462343,0.000639361,0.002063466,0.0005706203,0.0001776475,0.00004878802,0.000202086,0.001541009,0.0001015469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007760372,"about_ca_system_score_gemma":0.001917967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007910454,"about_ca_topic_score_gemma":0.0009205791,"domain_scores_codex":[0.9941099,0.000879672,0.002391619,0.00137683,0.00042491,0.000817011],"domain_scores_gemma":[0.9948391,0.00242851,0.0008747978,0.001151863,0.000118995,0.000586719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007420688,0.0006497075,0.004196567,0.0397701,0.001725487,0.0003066425,0.00001879161,0.000007018096,9.123617e-8,0.00003138106,0.09267303,0.8605469],"study_design_scores_gemma":[0.003275808,0.0002462354,0.0004095678,0.03242005,0.01329103,0.00001825991,0.000005742875,0.0001838585,8.408406e-7,0.000005623975,0.9495657,0.0005772858],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001486925,0.9915103,0.00007262461,0.001047879,0.001759044,0.003650974,0.0006248204,0.00006419964,0.001121444],"genre_scores_gemma":[0.00004977711,0.9849586,0.0006788155,0.003131931,0.002087777,0.002291009,0.0004146843,0.0001902169,0.006197129],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8599697,"threshold_uncertainty_score":0.9996058,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2943846365","doi":"10.1016/j.cllc.2019.05.003","title":"Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer Canada; Boehringer Ingelheim; British Microcirculation Society; Bayer; Boehringer Ingelheim España; AstraZeneca Canada; Roche; Genzyme; Eisai; Merck; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Oncology; Internal medicine; Lung cancer; Propensity score matching; Discontinuation; Cohort; Population; Proportional hazards model; Epidermal growth factor receptor; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.03061519318359427,"gpt":0.4080269110230662,"spread":0.3774117178394719,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003301934,0.0001891547,0.000615755,0.0001511059,0.00005386894,0.0000222924,0.00005498236,0.0001862624,0.0004409269],"category_scores_gemma":[0.0001369399,0.0001557031,0.00009014998,0.0002823123,0.00003590366,0.0001367181,0.0000233988,0.0002936272,0.00001077032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004646738,"about_ca_system_score_gemma":0.0002108299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008574352,"about_ca_topic_score_gemma":0.01090837,"domain_scores_codex":[0.9980728,0.00008240734,0.0008690665,0.0004946988,0.0002010749,0.0002799481],"domain_scores_gemma":[0.9990573,0.0003496322,0.0001637103,0.0002246181,0.0000620053,0.0001427634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00009608671,0.0001598528,0.9964238,0.0001016469,0.00008305651,0.000007948068,0.0001077395,0.0001446284,0.00002725436,0.00002091234,0.0001093176,0.002717703],"study_design_scores_gemma":[0.007058674,0.0001830259,0.9872525,0.0003172022,0.0001687236,4.139173e-7,0.000034137,0.004419724,0.00002337918,0.00002291144,0.0003476312,0.0001716179],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955235,0.0006991855,0.00002157504,0.001207293,0.0005887704,0.001493785,0.00009673671,0.00003809636,0.0003310395],"genre_scores_gemma":[0.9976158,0.00007316931,0.0001434587,0.0006933156,0.0002307607,0.0002416854,0.0003653392,0.00002439726,0.0006120625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01005094,"threshold_uncertainty_score":0.6349388,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4255131969","doi":"10.1016/j.cllc.2014.09.003","title":"Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Carboplatin; Tolerability; Lung cancer; Renal function; Urology; Gastroenterology; Creatinine; Kidney disease; Population; Oncology; Chemotherapy; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.007468378888666048,"gpt":0.3285392792150845,"spread":0.3210709003264185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003154481,0.0003100295,0.0009966444,0.0003742864,0.00005250704,0.00001288892,0.00009262554,0.0001297875,0.00005118899],"category_scores_gemma":[0.00004914231,0.0002056717,0.00008197949,0.001151355,0.0001268197,0.0001248588,0.00002927979,0.0003183455,3.151887e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006836432,"about_ca_system_score_gemma":0.0003873129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002473438,"about_ca_topic_score_gemma":0.01134873,"domain_scores_codex":[0.9975557,0.0001213933,0.0009092623,0.0006229249,0.000441405,0.0003492907],"domain_scores_gemma":[0.9983928,0.0003119,0.0004626867,0.0003626444,0.0002959862,0.000173957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01221559,0.003949537,0.9570333,0.0001166909,0.000918036,0.000004606174,0.0007801136,0.01015884,0.00000177392,0.000006970534,0.00001464903,0.01479984],"study_design_scores_gemma":[0.06890602,0.006896437,0.9163746,0.001012934,0.001242185,8.517887e-8,0.00004033161,0.005218702,0.00001647901,0.000002967757,0.00005646663,0.0002327815],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961505,0.0004509864,0.00008486684,0.0004238243,0.00006910235,0.002524736,0.0000799371,0.00001500408,0.0002010305],"genre_scores_gemma":[0.99806,0.0005746043,0.0003793779,0.0002577883,0.00002631241,0.0002932064,0.0002644402,0.0000400037,0.0001042523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05669043,"threshold_uncertainty_score":0.8387049,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3207399235","doi":"10.1016/j.cllc.2021.10.001","title":"Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Genotyping; Internal medicine; Oncology; ROS1; Guideline; Prospective cohort study; Clinical trial; Biomarker; Cancer; Genotype; Pathology; Adenocarcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.0745080612710012,"gpt":0.4738090828601803,"spread":0.3993010215891791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000272561,0.0003414969,0.001401843,0.00008989882,0.000114877,0.00002219542,0.0001561221,0.0002879213,0.0001076304],"category_scores_gemma":[0.000859966,0.0003041733,0.0004574563,0.0003388482,0.0001495114,0.00006662534,0.00008173197,0.0005100318,0.000002783476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008409891,"about_ca_system_score_gemma":0.00431724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001525377,"about_ca_topic_score_gemma":0.00124648,"domain_scores_codex":[0.9966742,0.0001256867,0.001551464,0.0008653491,0.0002720634,0.000511265],"domain_scores_gemma":[0.9939755,0.003649189,0.000490258,0.0004991713,0.001110879,0.0002749786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004417927,0.0003659037,0.9439234,0.00164347,0.0005757279,0.00007348487,0.0002282119,0.004115177,0.0005009299,0.00001489489,0.0003691702,0.04377175],"study_design_scores_gemma":[0.1123168,0.005517935,0.8083883,0.004380707,0.007010561,0.000003406501,0.002140298,0.03223603,0.01386077,0.00002491811,0.01292106,0.001199231],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826998,0.00848364,0.0004494447,0.000667567,0.003228039,0.002925307,0.0007170706,0.00006386767,0.0007652438],"genre_scores_gemma":[0.9421444,0.0007091617,0.05349016,0.0009072347,0.000616622,0.001186078,0.0002535896,0.0001078827,0.0005848765],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.135535,"threshold_uncertainty_score":0.9999411,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1986487287","doi":"10.1016/j.cllc.2012.06.005","title":"Improving Outcomes for High-Risk Patients With Early-Stage Non–Small-Cell Lung Cancer: Insights from Population-Based Data and the Role of Stereotactic Ablative Radiotherapy","year":2012,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Lymphadenectomy; Lymph node; Population; Randomized controlled trial; Cancer; Dissection (medical); Radiation therapy; Radiology; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03741369225080014,"gpt":0.3812306087150883,"spread":0.3438169164642881,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003652813,0.0006135114,0.003096089,0.00008557025,0.0001460395,0.00004795183,0.000389801,0.0003507622,0.00008300904],"category_scores_gemma":[0.0001097504,0.0003117742,0.0004364494,0.0001591998,0.0001757976,0.0001537906,0.0001230933,0.0005329414,7.156382e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006550667,"about_ca_system_score_gemma":0.0008559269,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02215293,"about_ca_topic_score_gemma":0.001959499,"domain_scores_codex":[0.9966618,0.0003210598,0.0013289,0.0009553854,0.0003745561,0.000358264],"domain_scores_gemma":[0.9920294,0.004071508,0.002078163,0.001387541,0.0002008838,0.0002325028],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006089043,0.0003503484,0.744121,0.004258767,0.003658857,9.160775e-7,0.0001074376,0.000003929896,1.645699e-8,0.00001012917,0.00004525696,0.2468345],"study_design_scores_gemma":[0.04186651,0.0009651169,0.7738644,0.01855778,0.07062397,2.22282e-7,0.00002431201,0.004322872,0.000003521919,0.00002064276,0.08875437,0.0009962231],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06538367,0.9223987,0.0001362359,0.00007230186,0.0006768477,0.006658714,0.004637141,0.00002322548,0.00001311335],"genre_scores_gemma":[0.0784032,0.9161214,0.000907821,0.0002219772,0.000616719,0.001924308,0.001544671,0.0001459616,0.0001139637],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2458383,"threshold_uncertainty_score":0.9999334,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2513734563","doi":"10.1016/j.cllc.2016.07.007","title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Astellas Foundation for Research on Metabolic Disorders","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Oncology; Placebo; Adverse effect; Pharmacology; Clinical endpoint; Cancer; Randomized controlled trial; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02682449255165086,"gpt":0.3907059977854347,"spread":0.3638815052337838,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001998596,0.0002711832,0.0006396679,0.0001769462,0.00007443549,0.0000155921,0.00007868922,0.0001196542,0.0001905864],"category_scores_gemma":[0.00016522,0.0001567179,0.00004663676,0.0004101931,0.0001328229,0.000226323,0.0000279004,0.0002606211,8.201686e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004388237,"about_ca_system_score_gemma":0.00066241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008990447,"about_ca_topic_score_gemma":0.001866105,"domain_scores_codex":[0.9979304,0.0001284264,0.0007849442,0.0005533583,0.0002920621,0.0003107821],"domain_scores_gemma":[0.9979573,0.0008354086,0.0004659879,0.0002139718,0.0003575642,0.0001697574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006812599,0.006754655,0.9596654,0.0001880828,0.0003805382,0.00001343167,0.004112491,0.00002066778,0.0001480559,0.000003994956,0.0001054569,0.02179462],"study_design_scores_gemma":[0.1331778,0.004997971,0.8571212,0.001696739,0.0004271973,8.816765e-7,0.0009629839,0.0004530038,0.0008512052,0.000003358776,0.00003880825,0.0002688674],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944659,0.0001264416,0.0001396088,0.0009092889,0.0001456675,0.003898659,0.0001573397,0.00002683035,0.0001302155],"genre_scores_gemma":[0.9975555,0.0001921615,0.0005277147,0.0002531273,0.00009251734,0.0008745905,0.00004174056,0.000055799,0.0004068799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1263652,"threshold_uncertainty_score":0.6390771,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120295366","doi":"10.3816/clc.2011.n.002","title":"Classification and Toxicities of Vascular Disrupting Agents","year":2011,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Headaches; Adverse effect; Pharmacology; Lung cancer; Anesthesia; Oncology; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.2931588339410363,"gpt":0.555318490067568,"spread":0.2621596561265316,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002845543,0.0002125292,0.001585622,0.0000671833,0.00002837487,0.000004486589,0.00007728043,0.00032115,0.0006766164],"category_scores_gemma":[0.0000654808,0.000155004,0.0005183883,0.0001006442,0.0001962408,0.00002542837,0.0000525504,0.0003224041,0.00000805697],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000111147,"about_ca_system_score_gemma":0.0003180988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000433632,"about_ca_topic_score_gemma":0.000009904671,"domain_scores_codex":[0.9984367,0.0001345648,0.0008258398,0.0003475847,0.00009846727,0.0001568501],"domain_scores_gemma":[0.9988229,0.0002884033,0.0004541164,0.0002478666,0.00005986668,0.0001268569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004058932,0.0001639367,0.01067251,0.01431646,0.001191242,0.000005425403,0.00005433251,1.571562e-8,3.716861e-7,0.00009049902,0.00363648,0.9698281],"study_design_scores_gemma":[0.0007372887,0.0001762973,0.00625861,0.007388952,0.006455446,0.000005269291,0.000007536611,0.00001681832,4.798275e-7,0.000009281432,0.9788119,0.000132151],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006477011,0.9958225,0.000003382405,0.00003555997,0.000727059,0.0007818034,0.00004593416,0.00002041026,0.001915675],"genre_scores_gemma":[0.0002920411,0.9971447,0.00006587601,0.000123431,0.0006478016,0.000207943,0.00006760131,0.00003367608,0.001416934],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9751754,"threshold_uncertainty_score":0.7408476,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2095154871","doi":"10.3816/clc.2009.n.030","title":"Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Lung cancer; Spinal cord compression; Oncology; Internal medicine; Cancer; Bisphosphonate; Pathologic fracture; Bone metastasis; Surgery; Metastasis; Osteoporosis","retraction":null,"screen_n_in":null,"score":{"opus":0.06245777038461617,"gpt":0.476516052412353,"spread":0.4140582820277368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003671176,0.0005117775,0.002773036,0.0001184859,0.00006871295,0.0000242886,0.0001190836,0.0003671393,0.0001015919],"category_scores_gemma":[0.0002415457,0.000346973,0.0003195682,0.0003919279,0.0001344918,0.00006318421,0.00005981391,0.0007275815,0.000005867313],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006808076,"about_ca_system_score_gemma":0.002324338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001325,"about_ca_topic_score_gemma":0.00269477,"domain_scores_codex":[0.9965913,0.0002109368,0.001295599,0.0009186486,0.0003946035,0.000588967],"domain_scores_gemma":[0.9975161,0.0002516933,0.0003871656,0.0005347483,0.0001810199,0.001129288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000463239,0.00047576,0.7057012,0.006948515,0.0004591269,0.00007501803,0.000003783895,4.15453e-7,7.859529e-10,0.000008349278,0.001483667,0.2843809],"study_design_scores_gemma":[0.003899979,0.0002377805,0.8239771,0.01928034,0.004826416,4.494944e-7,2.971387e-7,0.00001230986,1.191147e-8,0.000005517647,0.1474838,0.0002760272],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06817359,0.9255924,0.000004206282,0.0003243683,0.0005685515,0.004373058,0.000863898,0.00003745595,0.00006248948],"genre_scores_gemma":[0.01102784,0.9859787,0.00003294744,0.001375499,0.0002618608,0.0006784115,0.0003516964,0.00005661046,0.000236456],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2841049,"threshold_uncertainty_score":0.9998983,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}